We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+44.51%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
Cap. Flow
+$2.7M
Cap. Flow %
0.77%
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.42M
2
NUVL
Nuvalent
NUVL
+$7.29M
3
BIIB icon
Biogen
BIIB
+$6.21M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.88M
5
TERN
Terns Pharmaceuticals
TERN
+$4.56M

Top Sells

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$10.8M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.26M
3
AKRO
Akero Therapeutics
AKRO
+$5.48M
4
COGT icon
Cogent Biosciences
COGT
+$5.3M
5
NKTX icon
Nkarta
NKTX
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 79.93%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
26
GSK
GSK
$107B
$4.79M 1.37%
+136,178
New +$4.54M
VCYT icon
27
Veracyte
VCYT
$4.45B
$4.75M 1.36%
200,000
-465,854
-70% -$10.8M
KRYS icon
28
Krystal Biotech
KRYS
$10.7B
$4.64M 1.33%
58,535
+1,890
+3% +$140K
BCAB icon
29
BioAtla
BCAB
$5.34M
$4.51M 1.29%
10,938
+6,930
+173% +$2.88M
UTHR icon
30
United Therapeutics
UTHR
$26.1B
$4.46M 1.28%
16,048
+5,352
+50% +$1.35M
GILD icon
31
Gilead Sciences
GILD
$165B
$4.46M 1.28%
+51,962
New +$4.11M
PRTA icon
32
Prothena Corp
PRTA
$448M
$4.32M 1.24%
71,706
-38,294
-35% -$2.24M
MRUS
33
DELISTED
Merus
MRUS
$4.25M 1.22%
274,704
-20,432
-7% -$360K
PLRX icon
34
Pliant Therapeutics
PLRX
$65M
$4.2M 1.2%
217,503
+7,681
+4% +$161K
MGNX icon
35
MacroGenics
MGNX
$233M
$4.11M 1.18%
612,475
+512,475
+512% +$2.81M
ALLK
36
DELISTED
Allakos
ALLK
$4.05M 1.16%
480,701
+80,701
+20% +$561K
PCVX icon
37
Vaxcyte
PCVX
$7.65B
$3.99M 1.14%
+83,135
New +$3.26M
IMTX icon
38
Immatics
IMTX
$1.23B
$3.83M 1.1%
439,788
+275,850
+168% +$2.85M
VRTX icon
39
Vertex Pharmaceuticals
VRTX
$123B
$3.29M 0.94%
11,384
+279
+3% +$85K
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.42B
$3.12M 0.89%
272,173
+85,570
+46% +$1.07M
PNT
41
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$2.92M 0.84%
400,812
+100,812
+34% +$748K
RNAM
42
DELISTED
Avidity Biosciences
RNAM
$2.84M 0.81%
+128,000
New +$1.91M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.5B
$2.83M 0.81%
23,151
+18,151
+363% +$2.11M
CRNX icon
44
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.8M 0.8%
152,747
+3,720
+2% +$65.6K
PHR icon
45
Phreesia
PHR
$689M
$2.76M 0.79%
85,390
+2,085
+3% +$56.6K
ALT icon
46
CALL
Altimmune
ALT
$568M
$2.63M 0.75%
+160,000
New +$1.8M
HZNP
47
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.62M 0.75%
23,054
+12,923
+128% +$1.07M
INSM icon
48
Insmed
INSM
$22.4B
$2.49M 0.71%
124,465
-99,551
-44% -$1.92M
CLDX icon
49
Celldex Therapeutics
CLDX
$2.94B
$2.44M 0.7%
54,699
+1,424
+3% +$50.8K
CGEM icon
50
Cullinan Oncology
CGEM
$1.06B
$2.42M 0.69%
229,416
+4,861
+2% +$59K
1
2
3 4 5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management's Q4 2022 filing shows 29 new, 39 increased, 21 reduced and 18 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M. The largest sale was Veracyte, an estimated $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Technology.

  • Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
  • Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
  • Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
  • Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
  • Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.